Drug intelligence / Profile preview

fesoterodine

Development stage: Approved
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Fesoterodine is a small molecule antimuscarinic agent used to treat overactive bladder in adults and neurogenic detrusor overactivity in pediatric patients aged 6 years and older weighing more than 25 kg. It works by competitively antagonizing muscarinic acetylcholine receptors (M1–M5), leading to relaxation of the bladder muscle, increased bladder capacity, and reduced symptoms of urinary frequency, urgency, and urge incontinence. Fesoterodine is administered orally as an extended-release tablet. Its active metabolite is 5-hydroxymethyltolterodine.

Brand names: Toviaz
Other names: fesoterodine fumarate

Targets

CHRM2 (M2)CHRM3 (M3)

Beyond the preview

Go deeper on fesoterodine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fesoterodine.

Explore the full profile